MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.
Welcome
Alzheimer’s disease is an acquired disorder of cognitive and behavioural impairment that markedly interferes with social and occupational functioning. Alzheimer’s leads to progressive deficits in language, memory, comprehension, attention, judgment, and reasoning. It is the most common cause of cognitive decline in adults.
Alzheimer’s disease is a progressive condition that leads to dementia and loss of cognitive abilities in adults. It is the most common cause of dementia, representing 60 to 80 percent of dementia cases. Other types of dementia include vascular dementia, frontotemporal dementia, and Lewy body dementia (disease associated with abnormal deposits of a protein called alpha-synuclein in the brain)
Alzheimer’s is most often diagnosed in adults 65 years and older, though it can begin at younger ages. Alzheimer’s disease is incurable. The symptoms are progressive and ultimately lead to death.
The Alzheimer’s Society of Canada estimates that 597,000 adults aged 65 and older were living with Alzheimer’s and other forms of dementia in 2020. That number is projected to rise to 955,900 by 2030. Women account for nearly 62 percent of dementia cases in Canada, with men accounting for 38 percent of cases.
Worldwide, over 58 million people are affected by dementia. Alzheimer’s Disease International estimates that in 2020, dementia affected 12.7 million residents of Europe, 29.2 million residents of Asia, 5.3 million residents of Africa, and 11.4 million residents of North and South America.
Alzheimer’s is a type of neurological disease characterized by gradual and progressive neuronal cell death, typically beginning in the entorhinal cortex in the hippocampus. The damage is caused by the accumulation of abnormal neuritic plaques and neurofibrillary tangles.
The plaques, called beta-amyloid plaques, form microscopic lesions that contribute to brain cell damage. The neurofibrillary tangles may be a complication of the proliferation of beta-amyloid proteins. The presence of excessive beta-amyloid leads to hyperphosphorylation of a protein called tau. This causes the tangling of structures in nerve cells.
Both plaques and tangles are present in individuals with Alzheimer’s. However, neurofibrillary tangles are more strongly correlated with symptoms and diagnosis of Alzheimer’s than plaques. Beta-amyloid plaques can be present in individuals who do not have dementia.
There is no known trigger for Alzheimer’s. Evidence suggests there is a genetic component. Researchers have isolated two different genes that may be predictive of the development of Alzheimer’s: risk genes and deterministic genes. People with a parent or sibling with Alzheimer’s have a greater risk of developing the condition.
Other factors that may also play a role in developing Alzheimer’s include:
There is no cure for Alzheimer’s, however, there are four medications approved by Health Canada to treat dementia. These drugs do not cure the disease but can temporarily improve memory and focus:
The earliest symptoms of Alzheimer’s include memory loss and confusion. Over time, symptoms will worsen. Additional symptoms may emerge, including:
The earliest signs of Alzheimer’s are confusion and memory loss. Alzheimer’s affects learning, so individuals may have trouble remembering new information while retaining older memories. Confusion and mood swings are also characteristics of early dementia.
Formal diagnosis requires referral to a neurologist. The specialist can perform clinical evaluation, testing to rule out other diagnoses, and brain imaging studies to confirm the presence of beta-amyloid plaques.
Understanding the signs of Alzheimer’s and other types of dementia can help primary care providers better treat older adults. Join the MDBriefCase community for free to stay current on clinical guidelines.
199 Bay Street #4000, Toronto,
ON M5L 1A9
In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Lab website (the “Website”), you (“You”) expressly agree to the following:
Review: MDBriefCase is pleased to consider the publication of Your Work on the Website. The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.
Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered. If posted, You will be identified as the author of the Work, or co-author if applicable.
Grant of Rights: As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats: (1) the exclusive right of first publication worldwide; (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications. The grant of rights survives termination or expiration of this Agreement.
Warranty: You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work. This warranty survives termination or expiration of this Agreement.
Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.
The Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished. When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.
Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.
Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words.
MDBriefCase reserves the right to accept or reject any submission and the right to condition acceptance upon revision of material to conform to its criteria.
There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal websites, corporate websites and social media platforms.
Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement.
